NOT FOR PRODUCT PROMOTIONAL USE

Bank of AmericaMerrill Lynch

Health Care ConferenceGiovanni Caforio, M.D.

President, U.S. Pharmaceuticals

1

May 15, 2013

NOT FOR PRODUCT PROMOTIONAL USE

Forward-Looking Information and Non-GAAP Financial Information

During this meeting, we will make statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports onForm 10-Q and Form 8-K. These documents are available from the SEC, theBristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only asof today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

During this meeting, we will also discuss certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.

2

NOT FOR PRODUCT PROMOTIONAL USE

Agile, Entrepreneurial & Accountable Culture

Benchmark BioPharma Company

Our Strategic Foundation

Innovation SelectiveIntegration

ContinuousImprovement

3

Helping more patients prevail in their fight against serious disease

Best of PharmaBest of Biotech

NOT FOR PRODUCT PROMOTIONAL USE

A Diversified Product Portfolio

Key Brands

4

Q1 US revenue growth (ex. Plavix & Avapro) of 9%

NOT FOR PRODUCT PROMOTIONAL USE

Unique and differentiated profile

U.S. launch with Pfizer is under way

Near term life-cycle opportunities

5

Building a foundation for future leadership

NOT FOR PRODUCT PROMOTIONAL USE

Broad portfolio to address patient needs

U.S. alliance focused to deliver on long-term growth

Upcoming catalysts:

– SAVOR results mid-year

– Planned re-filing of Forxiga this summer

6

Diabetes: Establishing Leadership Position

NOT FOR PRODUCT PROMOTIONAL USE 7

Strong launch and continued growth

Leveraging potential for long-term survival

Leadership in immuno-oncology

– Nivolumab (anti-PD-1)

– Earlier stage assets

NOT FOR PRODUCT PROMOTIONAL USE

Confident in Our Future

Strong Growth

New Product Opportunities

Late-Stage Pipeline

8

Positioned for Long-Term Success

NOT FOR PRODUCT PROMOTIONAL USE

Bank of AmericaMerrill Lynch

Health Care ConferenceGiovanni Caforio, M.D.

President, U.S. Pharmaceuticals

9

May 15, 2013